Development and validation of subtype prediction scores for the workup of primary aldosteronism

OBJECTIVES:A subtype prediction score for primary aldosteronism has not yet been developed and validated using a large dataset. This study aimed to develop and validate a new subtype prediction score and to compare it with existing scores using a large multicenter database. METHODS:In total, 1936 pa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of hypertension 2018-11, Vol.36 (11), p.2269-2276
Hauptverfasser: Kobayashi, Hiroki, Abe, Masanori, Soma, Masayoshi, Takeda, Yoshiyu, Kurihara, Isao, Itoh, Hiroshi, Umakoshi, Hironobu, Tsuiki, Mika, Katabami, Takuyuki, Ichijo, Takamasa, Wada, Norio, Yoshimoto, Takanobu, Ogawa, Yoshihiro, Kawashima, Junji, Sone, Masakatsu, Inagaki, Nobuya, Takahashi, Katsutoshi, Watanabe, Minemori, Matsuda, Yuichi, Shibata, Hirotaka, Kamemura, Kohei, Yanase, Toshihiko, Otsuki, Michio, Fujii, Yuichi, Yamamoto, Koichi, Ogo, Atsushi, Nanba, Kazutaka, Tanabe, Akiyo, Suzuki, Tomoko, Naruse, Mitsuhide
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:OBJECTIVES:A subtype prediction score for primary aldosteronism has not yet been developed and validated using a large dataset. This study aimed to develop and validate a new subtype prediction score and to compare it with existing scores using a large multicenter database. METHODS:In total, 1936 patients with primary aldosteronism were randomly assigned to the development and validation datasets, constituting 1290 and 646 patients, respectively. Three prediction scores were generated with or without confirmatory tests, using logistic regression analysis. In the validation dataset, new and existing prediction scores were compared using receiver operating characteristic curve, net reclassification improvement, and integrated discrimination improvement analyses. RESULTS:The new prediction score is simply calculated using serum potassium levels [>3.9 mmol/l (four points); 3.5–3.9 mmol/l (three points)], the absence of adrenal nodules during computed tomography (three points), a baseline plasma aldosterone concentration of
ISSN:0263-6352
1473-5598
DOI:10.1097/HJH.0000000000001855